Skip to main content

SEREVENT DISKUS

LABA DPI

Salmeterol xinafoate · GlaxoSmithKline

Clinical Reference · Data reviewed June 2026

Active Medication & Mechanism

  • Salmeterol xinafoate LABA
    50 mcg salmeterol per blister

    Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (≥12 hours) via stimulation of beta2-receptors on airway smooth muscle. Onset is approximately 30–48 minutes.

FDA-Approved Dosing — Strength × Indication

50 mcg
Asthma FDA Approved
Adults (≥18 years, only with concomitant ICS) 1 inhalation twice daily (~12 hours apart) → 100 mcg For asthma, should only be used as additional therapy in patients NOT adequately controlled on ICS or whose disease warrants ICS + LABA. MUST be used WITH an ICS — salmeterol monotherapy in asthma increases the risk of asthma-related death.
COPD FDA Approved
1 inhalation twice daily (~12 hours apart) → 100 mcg Maintenance treatment of bronchospasm associated with COPD, including emphysema and chronic bronchitis.
Exercise-Induced Bronchospasm FDA Approved
1 inhalation at least 30 minutes before exercise → Should not exceed 1 inhalation twice daily Prevention of exercise-induced bronchospasm. Do not use additional doses for 12 hours. Patients already taking Serevent twice daily should NOT use additional doses for EIB.

All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling

Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.

Related Inhalers

For educational reference by healthcare professionals. Not medical advice and not for use in clinical decision-making. This workspace is not a substitute for clinical judgement, prescribing information, or product monographs — always verify doses and indications against the most current labelling. If you are a patient, do not use this site to make medication decisions — speak with your clinician.

Device images are original illustrations for identification aid only — actual devices and packaging may differ. This site is not affiliated with or endorsed by any pharmaceutical manufacturer. Clinical data last reviewed: June 2026.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved